Modelling Cost-Effectiveness of Biologic Treatments Based on Disease Activity Scores for the Management of Rheumatoid Arthritis in Spain

Table 4

Summary of effectiveness probabilities (percentage of patients achieving RS).

Biological agent		%RS	Source
Abatacept after IR to anti-TNF therapy	Induction—Month 12; Maintenance; Month 18; Month 24	11.1%; 13.9%; 17.1%	ATTAIN + LTE study (Genovese 2007); ATTAIN + LTE study (Genovese 2007); ATTAIN + LTE study (Genovese 2007)
Abatacept after IR to 2 anti-TNF agents	Induction—Month 18; Maintenance—Month 24	8.45%; 14.4%	ATTAIN reanalysis after IR to 2 anti-TNF agents; ATTAIN reanalysis after IR to 2 anti-TNF agents
Anti-TNF agents	Induction—Month 18; Maintenance—Month 24	4%; 14.4%	REACT trial (Bombardieri 2007); ATTAIN reanalysis after IR to 2 anti-TNF agents
Rituximab after IR to anti-TNF therapy	Induction—Month 12; Maintenance; Month 18; Month 24	6%; 13%; 12%	REFLEX + LTE study (Keystone 2007); REFLEX + LTE study (Keystone 2007); Keystone (EULAR 2007)
DMARDS	Month 24	1%	Clinical experts opinion

IR: insufficient response; RS: remission (DAS28 < 2.6).